NICE Sends Out Cost Warning By Flatly Rejecting Kadcyla On Price
This article was originally published in The Pink Sheet Daily
Executive Summary
Not inspired by its clinical effectiveness, NICE has said it will not recommend Roche's “over-priced” Kadcyla for breast cancer.
You may also be interested in...
Roche Won’t Match NICE's Excessive Discount Expectations For Kadcyla
A discount and even the fulfilment of end-of-life criteria have failed to save Kadcyla at NICE, putting the struggle between health systems’ sustainability and the need for R&D plus innovation in the spotlight.
European Notebook: Price Cuts Planned In France; IPO Window Thrown Open; European Big Pharmas Pursue Major Deals
Increased optimism about economic growth in Europe has been followed by IPOs becoming more common among the region’s biotech companies; there’s a speculation frenzy about M&A; and with European parliamentary elections in May, further regulatory and legislative changes are likely later in the year.
U.K. Coverage Rejection Of Alimta In NSCLC Increases Concerns About Access To Cancer Drugs
The U.K.’s NICE has rejected reimbursement under the National Health Service for Lilly’s Alimta in non-small cell lung cancer on cost grounds, prompting renewed calls to update or replace the U.K. Cancer Drugs Fund.